Lilly must add a vision-loss warning to its GLP-1 medicines, adding a safety concern for patients and doctors. The reported rate was 6.4 cases per 100,000 person-years, versus 3.8 in comparison groups, but another FDA comparison found no significant rise against one group of diabetes drugs.
For Lilly, a required warning adds a safety concern to Mounjaro, Zepbound, and Foundayo. Some patients or doctors may become more cautious, though Citi analysts said the rule should have limited effect on prescribing.
The evidence is mixed. The FDA found no statistically significant increase compared with one group of diabetes drugs, but found an increase compared with another. Earlier studies also found links, but did not prove the medicines caused the eye condition.
Novo’s Wegovy is covered by the new warning, adding a safety concern for patients and doctors. Novo says the evidence does not prove cause and effect, and analysts expect limited prescribing change, but the warning still weighs against its medicines.
DataMEDS’s interim co-CEO previously mentioned vision loss among side effects reported with GLP-1 apps. This report gives no new change to DataMEDS’s products or business, so its company outlook is unchanged.
Get alerts for LLY
Follow Eli Lilly and Co. (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.